Table 3 Potential inhibitors of the PI3K/AKT/mTOR pathway available for targeting mTOR.
From: Immunometabolism in cancer: basic mechanisms and new targeting strategy
Target | Drug | Phase/Status | Tumor type | Treatment | ClinicalTrials. govIdentifier |
|---|---|---|---|---|---|
PI3K/AKT/mTOR Inhibitors | |||||
mTOR | Everolimus | FDA approved for marketing | Advanced-stage renal cancer, advanced-stage HR+breast cancer in postmenopausal women in combination with exemestane, well-differentiated neuroendocrine tumors, renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex | Monotherapy With exemestane | |
Temsirolimus | FDA approved for marketing | Advanced renal cell carcinoma, | Monotherapy | ||
Rapamycin | I Completed | Bladder cancer | Monotherapy | ||
II Ongoing | Non-muscle invasive bladder cancer | With Encapsulated Rapamycin | |||
I/II Ongoing | Advanced soft tissue sarcoma, locally advanced soft tissue sarcoma, metastatic soft tissue sarcoma | With Nanoparticle Albumin-Bound Rapamycin, Pazopanib hydrochloride | |||
I Ongoing | Advanced malignant solid neoplasm, recurrent brain neoplasm, recurrent malignant solid neoplasm, refractory brain neoplasm | With Dasatinib, Cyclophosphamide | |||
IV Ongoing | Uterine fibroids | Monotherapy | |||
Ridaforolimus (MK-8669) | I Completed | Cancer, advanced | Monotherapy | ||
II Completed | Sarcoma | Monotherapy | |||
II Completed | Breast neoplasms | With Dalotuzumab, Exemestane | |||
Vistusertib (AZD2014) | II Completed | Diffuse large B-cell lymphoma | With Rituximab | ||
AZD8055 | I Completed | Glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, malignant glioma, brainstem glioma | Monotherapy | ||
Sapanisertib (MLN0128) | I Completed | Advanced solid tumors | Monotherapy | ||
II Ongoing | Non-small cell lung cancer | Monotherapy | |||
II Completed | Breast neoplasms | With Fulvestrant | |||
I Completed | Malignant solid neoplasm | With Carboplatin, Paclitaxel | |||
II Completed | Endometrial neoplasms | With Paclitaxel, MLN1117 | |||
CC-223 (ATG-008) | I Ongoing | Lymphoma, large B-cell, diffuse | With CC-122, Rituximab, CC-292 | ||
II Ongoing | Hepatocellular carcinoma | Monotherapy | |||
OSI‑027 | I Completed | Any solid tumor or lymphoma | Monotherapy | ||
